drugset / Trial / NCT06877676
Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
Summary
The purpose of this pre-approval access program is to provide access to TAR-200 prior to its marketing authorization for the treatment of participant(s) with high-risk non-muscle invasive bladder cancer (HR-NMIBC).
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAR-200 | Other / unclassified | — | Other |